RxDoctor Payments Data

Lucy Barnes

Family · Meridian, MSNPI 1659971380

Payments from drug & device makers

$683in general payments, 2019–2025

Across 26 payments — averaging $26.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$316
  • Teva Pharmaceuticals USA, Inc.$185
  • Otsuka America Pharmaceutical, Inc.$108
  • Acadia Pharmaceuticals Inc$26
  • AstraZeneca$20
  • Alkermes, Inc.$16
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$683100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$683 in reported general payments places this provider in the 60th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$13,721
Medicare patients
40
Services billed
191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide26$14,915
EliquisApixaban34$11,739
XareltoRivaroxaban35$7,242
FarxigaDapagliflozin Propanediol14$7,147
Mirtazapine68$2,295
Amlodipine Besylate126$1,632
Divalproex Sodium29$1,394
Baclofen26$1,225
Furosemide117$1,194
Gabapentin65$1,171
Atorvastatin Calcium80$1,167
Rosuvastatin Calcium32$1,144
Buspirone Hcl44$1,061
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide12$1,060
Escitalopram Oxalate63$1,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$316$14,91526 claims
PfizerEliquis$12$11,73934 claims
AstraZenecaFarxiga$20$7,14714 claims
Teva Pharmaceuticals USA, Inc.Albuterol Sulfate$185$38818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,007 family providers in Mississippi.

Other family in Meridian

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →